Mid-Stage Trial Shows Shionogi’s Peramivir Equal to Tamiflu, GSK’s Relenza
This article was originally published in PharmAsia News
Executive Summary
A Phase II trial in Japan has shown the drug peramivir developed by Japan's Shionogi and U.S.-based BioCryst effective in reducing flu symptoms. Researchers said the drug appears to be as effective as Tamiflu (oseltamivir) and GlaxoSmithKline's Relenza (zanamivir), the top drugs now used to treat influenza. Peramivir was tested against the other drugs in two different doses, using the same test the other drugs had faced. The head researcher said Shionogi's drug should be a good option for flu patients. (Click here for more